Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastroesophageal Reflux 1

Interventions

Bismuth 6Esomeprazole 5Amoxicillin 5Tetracycline 4Oxaliplatin 4apatinib 3Irinotecan 3Furazolidone 3Fluorouracil 3Clarithromycin 3fish oil triglycerides 2Rabeprazole 2Leucovorin 2Indocyanine Green 2Berberine 2sintilimab 1potassium oxonate 1lenvatinib 1iron isomaltoside 1000 1ilaprazole 1gimeracil 1ferric carboxymaltose 1doxifluridine 1alanylglutamine 1Water 1Trastuzumab 1Tranexamic Acid 1Tobacco Use Cessation Devices 1Thalidomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Stomach Neoplasms × ilaprazole × Clear all
NCT02638584 2020-07-31

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Il-Yang Pharm. Co., Ltd.

Phase 4 Completed
176 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡